{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:28:24Z","timestamp":1793831304905,"version":"4.6.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"21","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jacc.2025.08.101","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T18:39:14Z","timestamp":1762799954000},"page":"2000-2013","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Association of Lipoprotein(a) and Interleukin-6 With Cardiovascular Risk"],"prefix":"10.1016","volume":"86","author":[{"given":"Harpreet S.","family":"Bhatia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3005-268X","authenticated-orcid":false,"given":"James","family":"McParland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8013-4564","authenticated-orcid":false,"given":"Rishi","family":"Rikhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moyses","family":"Szklo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9834-9494","authenticated-orcid":false,"given":"Sotirios","family":"Tsimikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5927-9291","authenticated-orcid":false,"given":"Calvin","family":"Yeang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9071-3287","authenticated-orcid":false,"given":"Michael D.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2025.08.101_bib1","doi-asserted-by":"crossref","first-page":"6040","DOI":"10.3390\/jcm11206040","article-title":"Lipoprotein(a): evidence for role as a causal risk factor in cardiovascular disease and emerging therapies","volume":"11","author":"Bhatia","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacc.2025.08.101_bib2","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/CIRCULATIONAHA.124.069556","article-title":"Independence of lipoprotein(a) and low-density lipoprotein cholesterol\u2013mediated cardiovascular risk: a participant-level meta-analysis","volume":"151","author":"Bhatia","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.08.101_bib3","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2217\/bmm.11.60","article-title":"Oxidized phospholipids on ApoB-100\u2013containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events","volume":"5","author":"Taleb","year":"2011","journal-title":"Biomark Med"},{"key":"10.1016\/j.jacc.2025.08.101_bib4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa043175","article-title":"Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease","volume":"353","author":"Tsimikas","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.101_bib5","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/eurjpc\/zwae355","article-title":"The effects of colchicine on lipoprotein(a) and oxidized phospholipid associated cardiovascular disease risk","volume":"32","author":"Mohammadnia","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacc.2025.08.101_bib6","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0140-6736(12)60110-X","article-title":"The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis","volume":"379","author":"Swerdlow","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.08.101_bib7","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1194\/jlr.P052209","article-title":"IL-6 blockade by monoclonal antibodies inhibits apolipoprotein(a) expression and lipoprotein(a) synthesis in humans","volume":"56","author":"M\u00fcller","year":"2015","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacc.2025.08.101_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.athplu.2023.09.001","article-title":"Lipoprotein(a), interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: is there an association?","volume":"54","author":"Makris","year":"2023","journal-title":"Atheroscler Plus"},{"key":"10.1016\/j.jacc.2025.08.101_bib9","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.08.101_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.119211","article-title":"Interleukin-6 modifies lipoprotein(a) and oxidized phospholipids associated cardiovascular disease risk in a secondary prevention cohort","volume":"405","author":"Mohammadnia","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2025.08.101_bib11","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.jacc.2021.07.016","article-title":"High-sensitivity C-reactive protein modifies the cardiovascular risk of lipoprotein(a)","volume":"78","author":"Zhang","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.08.101_bib12","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jamacardio.2023.5605","article-title":"Lipoprotein(a), C-reactive protein, and cardiovascular risk in primary and secondary prevention populations","volume":"9","author":"Small","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.08.101_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.101409","article-title":"Association of lipoprotein(a) with major adverse cardiovascular events across hs-CRP: a systematic review and meta-analysis","volume":"3","author":"Alebna","year":"2024","journal-title":"JACC Adv"},{"key":"10.1016\/j.jacc.2025.08.101_bib14","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1001\/jama.286.3.327","article-title":"C-Reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus","volume":"286","author":"Pradhan","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.08.101_bib15","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/aje\/kwf113","article-title":"Multi-Ethnic Study of Atherosclerosis: objectives and design","volume":"156","author":"Bild","year":"2002","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jacc.2025.08.101_bib16","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1373\/clinchem.2016.270751","article-title":"Evaluation of lipoprotein(a) electrophoretic and immunoassay methods in discriminating risk of calcific aortic valve disease and incident coronary heart disease: the Multi-Ethnic Study of Atherosclerosis","volume":"63","author":"Cao","year":"2017","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacc.2025.08.101_bib17","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/ijo.2011.157","article-title":"Obesity modifies the association between plasma phospholipid polyunsaturated fatty acids and markers of inflammation: the Multi-Ethnic Study of Atherosclerosis","volume":"36","author":"Steffen","year":"2012","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.jacc.2025.08.101_bib18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41586-023-06592-6","article-title":"Plasma proteomic associations with genetics and health in the UK Biobank","volume":"622","author":"Sun","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jacc.2025.08.101_bib19","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans","volume":"134","author":"van der Valk","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.08.101_bib20","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1093\/eurheartj\/ehaa171","article-title":"Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a)","volume":"41","author":"Stiekema","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.08.101_bib21","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.jacc.2013.12.030","article-title":"Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a)","volume":"63","author":"Tsimikas","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.08.101_bib22","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/eurjpc\/zwae364","article-title":"Lipoprotein(a)-associated risk of atherosclerotic cardiovascular disease is independent of C-reactive protein","volume":"32","author":"Thomas","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacc.2025.08.101_bib23","doi-asserted-by":"crossref","first-page":"S767","DOI":"10.1016\/j.ekir.2024.11.1354","article-title":"WCN25-888 Design of the ZEUS trial: interleukin-6 inhibition with ziltivekimab for cardiovascular protection in chronic kidney disease","volume":"10","author":"Perkovic","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.jacc.2025.08.101_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.117461","article-title":"Comparison of interleukin-6 and high-sensitivity C-reactive protein for cardiovascular risk assessment: findings from the MESA study","volume":"390","author":"Ferreira","year":"2024","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2025.08.101_bib25","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/eurjpc\/zwad197","article-title":"Association of interleukin-6 and interleukin-18 with cardiovascular disease in older adults: Atherosclerosis Risk in Communities study","volume":"30","author":"Jia","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacc.2025.08.101_bib26","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1093\/eurheartj\/ehaa160","article-title":"Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial","volume":"41","author":"Ridker","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.08.101_bib27","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa2405182","article-title":"Inflammation, cholesterol, lipoprotein(a), and 30-year cardiovascular outcomes in women","volume":"391","author":"Ridker","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.101_bib28","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1001\/jamacardio.2025.1603","article-title":"AHA PREVENT equations and lipoprotein(a) for cardiovascular disease risk: insights from MESA and the UK Biobank","volume":"10","author":"Bhatia","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.08.101_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.117217","article-title":"Lipoprotein(a) and the pooled cohort equations for ASCVD risk prediction: the Multi-Ethnic Study of Atherosclerosis","volume":"381","author":"Bhatia","year":"2023","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2025.08.101_bib30","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.08.101_bib31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.08.101_bib32","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.08.101_bib33","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","article-title":"A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice","volume":"18","author":"Koschinsky","year":"2024","journal-title":"J Clin Lipidol"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725094811?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725094811?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:34:59Z","timestamp":1790109299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109725094811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":33,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0735109725094811"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2025.08.101","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of Lipoprotein(a) and Interleukin-6 With Cardiovascular Risk","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2025.08.101","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}